vapreotide

Vapreotide is a synthetic cyclic octapeptide analog of somatostatin, designed to have greater metabolic stability and a longer half-life than the natural hormone. It acts primarily as an agonist at somatostatin receptor subtypes SSTR2 and SSTR5, inhibiting the secretion of various peptides and hormones such as growth hormone, insulin, glucagon, and gastrointestinal hormones. Vapreotide reduces splanchnic blood flow and has been used for hemostasis in acute esophageal variceal bleeding in patients with cirrhotic liver disease. It also shows efficacy in AIDS-related diarrhea and has been studied for antitumor effects due to its ability to inhibit peptide release from neuroendocrine tumors. The drug was developed at Tulane University School of Medicine (patent rights) and further developed by Debiopharm Group; it was licensed to H3 Pharma for clinical development[1][4][7][9].

Brand names

SanvarSanvar IR

Other names

vapreotidumvapreotidaOctastatinD-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH-2D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH 2